These emerging treatments, Tirzepatide , represent a significant advancement in addressing metabolic dysfunction and possibly related disorders. These drugs are categorized as GLP-1 hormone agonists , indicating they function to emulate the endogenous GLP-1 substance , boosting insulin release an